Cue biopharma reports fourth quarter and full year 2022 financial results and recent business highlights

Boston, march 21, 2023 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific t cells directly within the patient's body, today reported fourth quarter and full year 2022 financial results.
CUE Ratings Summary
CUE Quant Ranking